BioNTech

BioNTech is a prominent German biotechnology firm founded in 2008, specializing in the development and manufacturing of active immunotherapies. The company focuses on patient-specific approaches to treat complex diseases, including cancer, through its advanced technology platform. By leveraging cutting-edge science, computational discovery, and novel vaccination technology, BioNTech aims to revolutionize the biopharmaceutical landscape with targeted therapeutic candidates that address unmet medical needs.

Operating on a global scale, BioNTech maintains 8 locations and employs 5,000-10,000 employees. The organization integrates diverse expertise across medical, scientific, and engineering disciplines to drive its robust clinical-stage pipeline. Meet BioNTech's team to understand the leadership and organizational structure driving these innovations. Their commitment to scalable manufacturing, rigorous clinical research, and high-quality drug development positions them as a significant leader in the competitive biotechnology sector.

Listed on the NASDAQ under the ticker BNTX, the company demonstrates significant market presence and financial stability. With reported annual revenue of $3.3B, BioNTech continues to invest heavily in research and development to expand its therapeutic portfolio and clinical reach. Explore financial highlights to review detailed metrics regarding their funding history, debt, and fiscal performance. As a key player in the global healthcare market, the firm remains dedicated to advancing next-generation medicine through its proprietary technology and strategic international partnerships.